<DOC>
	<DOCNO>NCT03020498</DOCNO>
	<brief_summary>In exploratory study , investigator look immune response difference age group two different influenza vaccine give identical twin , vaccine-naive young adult elderly participant .</brief_summary>
	<brief_title>B-cell Immunity Influenza ( SLVP017 ) - Years 2 ( 2010 ) &amp; 3 ( 2011 )</brief_title>
	<detailed_description>This exploratory study healthy child adult give either standard trivalent , inactivate influenza vaccine ( TIV ) live , attenuated influenza vaccine ( LAIV ) . There exclusion gender , ethnicity race . Following confirmation write informed consent , baseline blood sample draw study participant prior immunization . The volunteer enrol three group ( A , B , C ) immunize previous year 's seasonal influenza vaccine . The identical twin Groups A randomized receive different vaccine ( TIV LAIV ) twin . The non-twin child Group B also randomly assign receive either TIV LAIV . Non-twin elderly adult Group C give standard TIV . All participant receive single dose assign influenza vaccine , either intramuscular ( IM ) injection ( TIV ) intranasal application ( LAIV ) .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Healthy , ambulatory 817 year old identical twin , 830 year old nontwins , 70100 year old elderly nontwin adult . 2 . Willing complete informed consent process . 3 . Availability followup plan duration study least 28 day immunization . 4 . Acceptable medical history medical history vital sign . 1 . Prior vaccination seasonal TIV LAIV H1N1 . 2 . Prior offstudy vaccination current seasonal TIV LAIV 3 . Allergy egg egg product , vaccine component 4 . Lifethreatening reaction previous influenza vaccination 5 . Asthma history wheeze 6 . Active systemic serious concurrent illness , include febrile illness day vaccination 7 . History immunodeficiency ( include HIV infection ) 8 . Known suspected impairment immunologic function , include , limited , clinically significant liver disease , diabetes mellitus treat insulin , moderate severe renal disease , chronic disorder , opinion investigator , might jeopardize volunteer safety compliance protocol . 9 . Blood pressure &gt; 150 systolic &gt; 95 diastolic first study visit 10 . Hospitalization past year congestive heart failure emphysema . 11 . Chronic Hepatitis B C. 12 . Recent current use immunosuppressive medication , include systemic glucocorticoid ( corticosteroid nasal spray topical steroid permissible group ; inhale steroid use permissible except nonLAIV Group C ) . Use oral steroid ( &lt; 20mg prednisoneequivalent/day ) may acceptable volunteer 70100 yrs age review investigator . 13 . Participants close contact anyone severely weaken immune system receive LAIV ( Groups A B ) 14 . Malignancy , squamous cell basal cell skin cancer ( include solid tumor breast cancer prostate cancer recurrence past year , hematologic cancer leukemia ) . 15 . Autoimmune disease ( include rheumatoid arthritis treat immunosuppressive medication Plaquenil , methotrexate , prednisone , Enbrel ) , opinion investigator , might jeopardize volunteer safety compliance protocol . 16 . History blood dyscrasia , renal disease , hemoglobinopathies require regular medical follow hospitalization precede year 17 . Use anticoagulation medication Coumadin Lovenox , antiplatelet agent aspirin ( except 325 mg. per day ) , Plavix , Aggrenox must review investigator determine would affect volunteer 's safety . 18 . Receipt blood blood product within past 6 month 19 . Medical psychiatric condition occupational responsibility preclude participant compliance protocol 20 . Inactivated vaccine 14 day prior vaccination 21 . Live , attenuate vaccine within 60 day vaccination 22 . History GuillainBarr√© Syndrome 23 . Pregnant lactate woman 24 . Use investigational agent within 30 day prior enrollment 25 . Donation equivalent unit blood within 6 week prior enrollment 26 . Any condition , opinion investigator , might interfere volunteer safety , study objective ability participant understand comply study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Inactivated influenza vaccine</keyword>
	<keyword>Live , attenuate influenza vaccine</keyword>
	<keyword>Child identical twin non-twins</keyword>
	<keyword>Young elderly non-twin adult</keyword>
</DOC>